Zymeworks BC Inc [ZYME] stock prices are up 0.66% to $18.23 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ZYME shares have gain 10.48% over the last week, with a monthly amount glided 14.44%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Zymeworks BC Inc [NASDAQ: ZYME] stock has seen the most recent analyst activity on October 14, 2025, when H.C. Wainwright upgraded its rating to a Buy but kept the price target unchanged to $26 for it. Previously, B. Riley Securities started tracking the stock with Buy rating on October 10, 2025, and set its price target to $30. On May 20, 2025, TD Cowen initiated with a Buy rating. JP Morgan upgraded its rating to a Overweight but stick to its price target of $18 on December 16, 2024. Leerink Partners upgraded its rating to a Outperform and raised its price target to $25 on November 07, 2024. Wells Fargo downgraded its rating to Equal Weight for this stock on November 01, 2024, but kept the price target unchanged to $12.
The stock price of Zymeworks BC Inc [ZYME] has been fluctuating between $9.03 and $18.49 over the past year. Currently, Wall Street analysts expect the stock to reach $26 within the next 12 months. Zymeworks BC Inc [NASDAQ: ZYME] shares were valued at $18.23 at the most recent close of the market. An investor can expect a potential return of 42.62% based on the average ZYME price forecast.
Analyzing the ZYME fundamentals
The Zymeworks BC Inc [NASDAQ:ZYME] reported sales of 122.87M for trailing twelve months, representing a surge of 153.21%. Gross Profit Margin for this corporation currently stands at 0.95% with Operating Profit Margin at -0.67%, Pretax Profit Margin comes in at -0.55%, and Net Profit Margin reading is -0.6%. To continue investigating profitability, this company’s Return on Assets is posted at -0.18, Equity is -0.22 and Total Capital is -0.22. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Zymeworks BC Inc [NASDAQ:ZYME]’s Current Ratio is 7.69. In addition, the Quick Ratio stands at 7.69 and the Cash Ratio stands at 2.55. Considering the valuation of this stock, the price to sales ratio is 11.24, the price to book ratio is 4.11.
Transactions by insiders
Recent insider trading involved EcoR1 Capital, LLC, Director, that happened on May 15 ’25 when 49502.0 shares were purchased. Director, EcoR1 Capital, LLC completed a deal on May 19 ’25 to buy 5919.0 shares. Meanwhile, Director EcoR1 Capital, LLC bought 73953.0 shares on Apr 16 ’25.
